You have full text access to this OnlineOpen article

The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder

  1. Roger Dmochowski1,
  2. Karl Kreder1,
  3. Scott MacDiarmid2,
  4. Martin Carlsson3,
  5. Zhonghong Guan3

Article first published online: 5 JUN 2007

DOI: 10.1111/j.1464-410X.2007.06926.x

Issue

BJU International

BJU International

Volume 100, Issue 1, pages 107–110, July 2007

Additional Information

How to Cite

Dmochowski, R., Kreder, K., MacDiarmid, S., Carlsson, M. and Guan, Z. (2007), The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU International, 100: 107–110. doi: 10.1111/j.1464-410X.2007.06926.x

Author Information

  1. 1

    Department of Urology, Vanderbilt University Medical Center, Nashville, TN, University of Iowa Hospitals and Clinics, Iowa City, IA,

  2. 2

    Department of Urology, Wake Forest University Baptist Medical Center, Winston-Salem, NC and

  3. 3

    Pfizer Inc, New York, NY, USA

*Roger Dmochowski, Department of Urology, Medical Center North, Room A 1302, Vanderbilt University Medical Center, Nashville, TN 37232, USA. e-mail: roger.dmochowski@vanderbilt.edu

Publication History

  1. Issue published online: 5 JUN 2007
  2. Article first published online: 5 JUN 2007
  3. Accepted for publication 25 January 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (90K)

Keywords:

  • bladder diaries;
  • efficacy;
  • overactive bladder;
  • tolterodine extended-release

OBJECTIVE

To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI).

PATIENTS AND METHODS

We conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (≥8 voids/24 h) and UUI (≥5 episodes/week) for ≥ 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight.

RESULTS

Compared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval.

CONCLUSIONS

These results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.

View Full Article (HTML) Get PDF (90K)